Goldman Sachs SELL

Sanofi (SASY.PA) Amlitelimab discontinued in AD, despite positive ESTURY data first move under the new CEO

Jul 24, 2026

From the report报告摘录Pipeline Reset: Sanofi halts amitilimab for AD due to clinical data failing to show meaningful improvement over standards, driven by new CEO's external review, causing 4% DCF downside and 2026 impairment charge.

Read the full report + PDF阅读全文与 PDF

The full summary (3 key points) and the original Goldman Sachs PDF are for Mastermind Pro members. 完整摘要（3 个要点）与 Goldman Sachs 原始 PDF 为 Mastermind Pro 会员专享。

Read on Mastermind前往 Mastermind 阅读

Related institutional research相关机构研报

Not investment advice. Mastermind hosts third-party institutional research for reference and education; ratings and views are the authors', not ours. Browse the full Research Vault → 非投资建议。Mastermind 仅收录第三方机构研究，供参考与学习；其中评级与观点均属作者本人。浏览完整研报库 →